AU2055300A - Methods for detection and use of differentially expressed genes in disease states - Google Patents
Methods for detection and use of differentially expressed genes in disease statesInfo
- Publication number
- AU2055300A AU2055300A AU20553/00A AU2055300A AU2055300A AU 2055300 A AU2055300 A AU 2055300A AU 20553/00 A AU20553/00 A AU 20553/00A AU 2055300 A AU2055300 A AU 2055300A AU 2055300 A AU2055300 A AU 2055300A
- Authority
- AU
- Australia
- Prior art keywords
- detection
- methods
- disease states
- differentially expressed
- expressed genes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000001514 detection method Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11300898P | 1998-12-18 | 1998-12-18 | |
| US60113008 | 1998-12-18 | ||
| PCT/US1999/029941 WO2000035473A2 (en) | 1998-12-18 | 1999-12-15 | Methods for detection and use of differentially expressed genes in disease states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2055300A true AU2055300A (en) | 2000-07-03 |
Family
ID=22347087
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU20553/00A Abandoned AU2055300A (en) | 1998-12-18 | 1999-12-15 | Methods for detection and use of differentially expressed genes in disease states |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1140137A2 (en) |
| AU (1) | AU2055300A (en) |
| WO (1) | WO2000035473A2 (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2360282A (en) * | 2000-03-17 | 2001-09-19 | Bioinvent Int Ab | Making and using micro-arrays of biological materials |
| US20040086857A1 (en) * | 2000-03-29 | 2004-05-06 | Kyoko Takeuchi | Proliferative glomerular nephritis-associated gene |
| US6800455B2 (en) * | 2000-03-31 | 2004-10-05 | Scios Inc. | Secreted factors |
| US20020142284A1 (en) * | 2000-07-13 | 2002-10-03 | Debasish Raha | Methods of identifying renal protective factors |
| IL154794A0 (en) * | 2000-09-08 | 2003-10-31 | Daiichi Suntory Pharma Co Ltd | Remedies for heart failure |
| AU2002218026A1 (en) | 2000-11-09 | 2002-05-21 | The Brigham And Women's Hospital, Inc. | Cardiovascular disease diagnostic and therapeutic targets |
| US20040101878A1 (en) * | 2000-12-22 | 2004-05-27 | Jones Michael H. | High-throughput screening system by microarrays |
| CA2448253A1 (en) * | 2001-05-25 | 2002-11-28 | Genset S.A. | Human cdnas and proteins and uses thereof |
| ATE403149T1 (en) * | 2001-08-13 | 2008-08-15 | Dana Farber Cancer Inst Inc | PERIOSTIN-BASED DIAGNOSTIC TESTS |
| GB0120238D0 (en) * | 2001-08-20 | 2001-10-10 | Univ College Of London | Sodium channel regulators and modulators |
| WO2003023066A1 (en) * | 2001-09-11 | 2003-03-20 | The Regents Of The University Of Colorado, A Body Corporate | Expression profiling in the intact human heart |
| WO2003094856A2 (en) | 2002-05-09 | 2003-11-20 | The Brigham And Women's Hospital, Inc. | 1l1rl-1 as a cardiovascular disease marker and therapeutic target |
| US8008003B2 (en) * | 2002-11-15 | 2011-08-30 | Genomic Health, Inc. | Gene expression profiling of EGFR positive cancer |
| US20060275770A1 (en) * | 2002-11-27 | 2006-12-07 | Daniel Bednarik | Heart failure gene determination and therapeutic screening |
| US8501473B2 (en) | 2003-07-16 | 2013-08-06 | Evotec International Gmbh | Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| JP2007537711A (en) | 2003-10-03 | 2007-12-27 | ジェネンテック・インコーポレーテッド | IGF binding protein |
| BRPI0518884A2 (en) * | 2004-12-08 | 2008-12-30 | Aventis Pharma Inc | Method for measuring resistance or sensitivity to docetaxel |
| WO2006085482A1 (en) * | 2005-02-10 | 2006-08-17 | Riken | Self-replication factor and amplification method of hematopoietic stem cell |
| WO2007103541A2 (en) | 2006-03-09 | 2007-09-13 | The Trustees Of Boston University | Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells |
| PL2386860T4 (en) | 2006-04-24 | 2015-09-30 | Critical Care Diagnostics Inc | Predicting mortality and detecting severe disease |
| ATE545032T1 (en) | 2006-05-01 | 2012-02-15 | Critical Care Diagnostics Inc | DIAGNOSIS OF CARDIOVASCULAR DISEASE |
| US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| ES2548009T3 (en) * | 2007-01-25 | 2015-10-13 | F. Hoffmann-La Roche Ag | Use of IGFBP-7 in the evaluation of heart failure |
| WO2009117791A2 (en) * | 2008-03-28 | 2009-10-01 | Katholieke Universiteit Leuven | Mucosal gene signatures |
| PT3093663T (en) | 2008-04-18 | 2018-10-19 | Critical Care Diagnostics Inc | Predicting risk of major adverse cardiac events |
| JP5706821B2 (en) * | 2008-09-08 | 2015-04-22 | オタワ ホスピタル リサーチ インスティテュート | Pancreatic regeneration induced by periostin |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| EP2513336B1 (en) * | 2009-12-16 | 2016-03-02 | Hitachi Chemical Co., Ltd. | Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers |
| EP2531614B1 (en) * | 2010-02-05 | 2018-07-18 | The Procter and Gamble Company | Transcriptional profiling and biomarker-based methods for identifying and evaluating agents for antioxidant efficacy in cosmetic skin care formulations |
| US9150920B2 (en) | 2010-05-07 | 2015-10-06 | Hitachi Chemical Co., Ltd. | Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers |
| CN103517990A (en) | 2010-10-07 | 2014-01-15 | 通用医疗公司 | Biomarkers of cancer |
| ES2750126T3 (en) | 2011-03-17 | 2020-03-25 | Critical Care Diagnostics Inc | Procedures for predicting the risk of an adverse clinical outcome |
| WO2013063035A1 (en) * | 2011-10-24 | 2013-05-02 | The General Hospital Corporation | Biomarkers of cancer |
| US20150056190A1 (en) * | 2012-03-30 | 2015-02-26 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
| CN111834009A (en) | 2012-08-21 | 2020-10-27 | 重症监护诊断股份有限公司 | Multi-marker risk stratification |
| US20160273047A1 (en) * | 2013-10-30 | 2016-09-22 | Servicio Andaluz Ed Salud | Epithelial-mesenchymal transition in circulating tumor cells (ctcs) negatives for cytokeratin (ck) expression in patients with non-metastatic breast cancer |
| AU2015259571B2 (en) * | 2014-05-12 | 2021-04-15 | Janssen Pharmaceutica Nv | Biological markers for identifying patients for treatment with abiraterone acetate |
| US10301624B2 (en) | 2014-06-25 | 2019-05-28 | The General Hospital Corporation | Targeting human satellite II (HSATII) |
| WO2016040643A1 (en) * | 2014-09-10 | 2016-03-17 | The Uab Research Foundation | Amyotrophic lateral sclerosis (als) biomarkers and uses thereof |
| WO2016046640A2 (en) | 2014-09-26 | 2016-03-31 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness |
| EP3212809A1 (en) * | 2014-10-29 | 2017-09-06 | Avon Products, Inc. | Screening method for identifying active agents |
| US20160199399A1 (en) * | 2015-01-09 | 2016-07-14 | Medical Prognosis Institute A/S | Methods for predicting drug responsiveness in cancer patients |
| JP6974182B2 (en) * | 2015-03-04 | 2021-12-01 | ハミングバード・ダイアグノスティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングHummingbird Diagnostics GmbH | Health sign |
| DE112016003948T5 (en) | 2015-08-31 | 2018-05-09 | City Of Sapporo | MOLECULAR METHODS FOR EVALUATING A UROTHIAL DISEASE |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| US10865412B2 (en) * | 2016-11-04 | 2020-12-15 | Ottawa Heart Institute Research | Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| US20200110073A1 (en) * | 2018-10-04 | 2020-04-09 | The Jackson Laboratory | Renal disease targets |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07132095A (en) * | 1993-06-11 | 1995-05-23 | Nawata Arata | Dna and protein coded thereby |
| AU3126595A (en) * | 1994-07-18 | 1996-02-16 | Georgetown University | Antisense oligonucleotides of pleiotrophin |
| ID27813A (en) * | 1998-01-28 | 2001-04-26 | Corixa Corp | COMPOUNDS FOR THERAPY AND DIAGNOSIS OF LUNG CANCER AND METHODS FOR USE |
-
1999
- 1999-12-15 AU AU20553/00A patent/AU2055300A/en not_active Abandoned
- 1999-12-15 EP EP99964277A patent/EP1140137A2/en not_active Ceased
- 1999-12-15 WO PCT/US1999/029941 patent/WO2000035473A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000035473A2 (en) | 2000-06-22 |
| WO2000035473A3 (en) | 2000-11-09 |
| EP1140137A2 (en) | 2001-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2055300A (en) | Methods for detection and use of differentially expressed genes in disease states | |
| AUPP784398A0 (en) | Kidney disease detection and treatment | |
| GB2325765B (en) | Data hiding and detection methods | |
| AU1603199A (en) | Methods and devices for measuring differential gene expression | |
| AU1807300A (en) | Detection of loss of heterozygosity in tumor and serum of melanoma patients | |
| AU3364099A (en) | Diagnosis of disease state using mrna profiles in peripheral leukocytes | |
| AU1047901A (en) | Methods of genetic cluster analysis and use thereof | |
| AU6028598A (en) | Non-iron metalloporphyrins and methods of use | |
| AU6534898A (en) | Detection of double-stranded dna in a homogeneous solution | |
| AU6057296A (en) | DNA sequencing and DNA terminators | |
| AU2001235829A1 (en) | Mutations in spink5 responsible for netherton's syndrome and atopic diseases | |
| AU2001285018A1 (en) | Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer | |
| AU4668196A (en) | Detection of mutations or variations in dna | |
| AU3454899A (en) | Methods of separation and detection | |
| AU2001234775A1 (en) | Direct detection and mutation analysis of low copy number nucleic acids | |
| AU4328399A (en) | Nucleic acid-cobalamin complexes and their use in gene therapy | |
| AU8225398A (en) | Biosensor materials and methods | |
| AU5260598A (en) | Detection of mutations in the human atm gene | |
| AU6629298A (en) | Interactions of skn7 gene and its use in assay methods | |
| AU2584699A (en) | Immediate early genes and methods of use therefor | |
| AU8271998A (en) | Methods of disease detection | |
| AU3187399A (en) | Mutations in mitotic check point genes and methods of diagnosis | |
| AU5962599A (en) | Detection of mutations in nucleic acids | |
| AU5319400A (en) | Molecules for disease detection and treatment | |
| AU2001286541A1 (en) | Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |